We create innovative treatments for nervous system damage due to injury or disease.
NervGen Pharma
NervGen (TSX-V: NGEN, OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments to enable nervous system repair in the settings of traumatic injury and disease. Our lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial in the company’s initial target indication, spinal cord injury. NervGen is evaluating a new discovery lead, NVG-300, in a preclinical model of ischemic stroke and confirmatory SCI study.
Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury
NervGen is actively recruiting for a landmark Phase 1b/2a proof-of-concept clinical trial of
NVG-291 in individuals with spinal cord injury.
For information regarding recruitment, the call center phone number is +1 (855) 559-6902.
Stay Connected
Subscribe to our mailing list to stay up to date
The Latest
NEWS RELEASE
November 18, 2025
NervGen announced it is conducting a non-brokered private placement to certain institutional investors and other accredited investors. The financing will include participation from new and existing investors, including SCI Ventures and the Paul and Phyllis Fireman Charitable Foundation.
News Release
August 26, 2025
NervGen announced its second quarter 2025 financial results, including a letter to shareholders from Adam Rogers, MD, Chairman and Interim CEO, providing a detailed business update.
News Release
August 21, 2025
NervGen announced positive preclinical results of two Department of Defense sponsored studies in models of blast-induced sensorineural hearing loss and PNI, reinforcing the broad therapeutic application of NVG-291.
